Cargando…

Retrospective analysis of the clinical and demographic variables on the outcomes after second-line treatment in advanced non-small cell lung cancer

BACKGROUND: Platinum based doublets chemotherapy are the standard of care for metastatic or advanced non-small cell lung carcinoma. This leads to modest survival advantage and improve quality-of-life. However, patients with advanced or metastatic disease eventually present disease progression and ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sau, Sourav, Biswas, Anirban, Roy, Amitava, Sau, Saikat, Ganguly, Subir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932595/ https://www.ncbi.nlm.nih.gov/pubmed/24604957 http://dx.doi.org/10.4103/0971-5851.125244

Ejemplares similares

Baseline Demographic Profile and General Health Influencing the Post-Radiotherapy Health Related Quality-of-Life in Women with Gynaecological Malignancy Treated with Pelvic Irradiation
por: Sau, Sourav, et al.
Publicado: (2013)

Biochemical characterization of L1 repressor mutants with altered operator DNA binding activity
por: Bandhu, Amitava, et al.
Publicado: (2012)

Repressor of temperate mycobacteriophage L1 harbors a stable C-terminal domain and binds to different asymmetric operator DNAs with variable affinity
por: Ganguly, Tridib, et al.
Publicado: (2007)

The role of second-line chemotherapy in small cell lung cancer: a retrospective analysis
por: Zarogoulidis, Konstantinos, et al.
Publicado: (2013)

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
por: Felip, Enriqueta, et al.
Publicado: (2008)

A comparative study of different dose fractionations schedule of thoracic radiotherapy for pain palliation and health-related quality of life in metastatic NSCLC
por: Sau, Sourav, et al.
Publicado: (2014)

Outcomes of Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in One Institution
por: Lee, Seok Jeong, et al.
Publicado: (2014)

Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer
por: Hirata, Tsuyoshi, et al.
Publicado: (2023)

Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib
por: Melosky, B., et al.
Publicado: (2008)

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
por: Ko, Yoon Ho, et al.
Publicado: (2007)

Efficiency and toxicity of nab-paclitaxel and camrelizumab in the second or above line treatment of advanced non-small cell lung cancer: a retrospective cohort study
por: Yin, Chen, et al.
Publicado: (2023)

Efficacy and safety of second‐line chemotherapy for patients with advanced non‐small cell lung cancer complicated by interstitial lung disease
por: Otsuka, Kenji, et al.
Publicado: (2022)

First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view
por: Thatcher, Nicholas
Publicado: (2008)

Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
por: Rothschild, Sacha I
Publicado: (2014)

A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma
por: Jin, Feng, et al.
Publicado: (2016)

A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer
por: Ji, Sang Hoon, et al.
Publicado: (2009)

Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice
por: Krainhöfer, Josephine, et al.
Publicado: (2014)

The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Song, Ik-Chan, et al.
Publicado: (2015)

A prognostic model for platinum‐doublet as second‐line chemotherapy in advanced non‐small‐cell lung cancer patients
por: Mo, Hongnan, et al.
Publicado: (2016)

A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma
por: Rodríguez-Cid, Jerónimo Rafael, et al.
Publicado: (2021)

Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
por: Gao, Guanghui, et al.
Publicado: (2022)

First-line Rucaparib Plus Bevacizumab Maintenance Completed One-Year in Germline BRCA1-Mutated Advanced Ovarian Cancer
por: Roy, Somnath, et al.
Publicado: (2022)

Supportive Care Costs Associated with Second-Line Chemotherapy in Chinese Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study
por: Li, Xiaoling, et al.
Publicado: (2015)

Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer
por: Lazzari, Chiara, et al.
Publicado: (2017)

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
por: Möhring, Christian, et al.
Publicado: (2021)

Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
por: Franchi, Matteo, et al.
Publicado: (2022)

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
por: Zhou, Dongchu, et al.
Publicado: (2022)

A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer
por: Xu, Yinghui, et al.
Publicado: (2022)

Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study
por: Fang, Xiaoxu, et al.
Publicado: (2023)

Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy
por: Fiteni, Frédéric, et al.
Publicado: (2014)

The clinical outcomes of second-line chemotherapy in patients with advanced pancreatic cancer: a retrospective study
por: Jung, Hyun yeb, et al.
Publicado: (2021)

Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models
por: Hubaux, Roland, et al.
Publicado: (2015)

NGR‐hTNF and Doxorubicin as Second‐Line Treatment of Patients with Small Cell Lung Cancer
por: Gregorc, Vanesa, et al.
Publicado: (2018)

Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib
por: Zugazagoitia, Jon, et al.
Publicado: (2017)

Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined
por: Chouaïd, Christos, et al.
Publicado: (2020)

An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer
por: Patel, Shetal, et al.
Publicado: (2021)

Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update
por: Prabhash, Kumar
Publicado: (2019)

Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer
por: Li, Ning, et al.
Publicado: (2014)

Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China
por: Zhang, Chunxiang, et al.
Publicado: (2016)

Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer
por: Zhang, Fan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_psbeb2egsq0ups78o2qfqtqu2q